Rhythm Pharmaceuticals is expected to announce top-line results from its ongoing Phase 3 trials exploring setmelanotide as an obesity…
Alice Melao
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Alice Melao
A large-scale genetic screening identified 24 new genetic variants implicated in the distribution of body fat. Conducted by researchers from…
Females have greater susceptibility than males to increased body fat content under a high-fat, high-sugar diet, a study in mice shows.
Kidney disease may be a primary manifestation of Alström syndrome. However, the development of renal problems may be nourished…
A new type of mutation affecting the BBS1 gene was identified in a patient diagnosed with Bardet-Biedl syndrome (BBS), a…
Phase 3 Trial of Setmelanotide in Controlling Hunger in Alström and Bardet-Biedl Patients Opens
With its first enrollee, Rhythm Pharmaceuticals has begun a pivotal Phase 3 trial to assess the therapeutic benefits of…